Shares of The Beauty Health Company (NASDAQ:SKIN – Get Free Report) have earned a consensus rating of “Hold” from the eight research firms that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, six have given a hold recommendation and one has assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $2.02.
A number of research analysts recently weighed in on the stock. Canaccord Genuity Group lowered their price objective on shares of Beauty Health from $1.50 to $1.00 and set a “hold” rating on the stock in a research report on Friday, May 1st. Benchmark reissued a “hold” rating on shares of Beauty Health in a research report on Friday, March 13th. TD Cowen decreased their target price on shares of Beauty Health from $1.65 to $1.50 and set a “hold” rating on the stock in a research note on Monday, March 16th. Zacks Research raised Beauty Health from a “strong sell” rating to a “hold” rating in a report on Monday, March 16th. Finally, Roth Mkm reaffirmed a “buy” rating and set a $2.00 price objective (down from $2.50) on shares of Beauty Health in a report on Wednesday, May 20th.
Check Out Our Latest Stock Analysis on SKIN
Hedge Funds Weigh In On Beauty Health
Beauty Health Price Performance
NASDAQ SKIN opened at $0.61 on Friday. Beauty Health has a one year low of $0.55 and a one year high of $2.69. The stock has a 50-day moving average of $0.80 and a 200 day moving average of $1.14. The company has a debt-to-equity ratio of 4.37, a quick ratio of 1.48 and a current ratio of 1.79. The company has a market capitalization of $78.74 million, a price-to-earnings ratio of -3.57 and a beta of 1.09.
Beauty Health (NASDAQ:SKIN – Get Free Report) last posted its earnings results on Thursday, May 7th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.04. Beauty Health had a negative net margin of 2.03% and a negative return on equity of 9.38%. The business had revenue of $64.91 million for the quarter, compared to analysts’ expectations of $66.28 million. On average, sell-side analysts forecast that Beauty Health will post -0.14 EPS for the current year.
About Beauty Health
Beauty Health Company (NASDAQ: SKIN) is a U.S.-based consumer wellness and beauty enterprise that integrates device-based and product-based offerings across skin, body and hair wellness categories. The company operates a portfolio of established brands that blend professional and at-home solutions, focusing on innovative formulations and technologies to address a range of beauty and self-care needs. Through its proprietary e-commerce platforms and strategic retail partnerships, Beauty Health seeks to deliver premium experiences and tangible results to a global customer base.
Beauty Health’s brand portfolio includes Sol de Janeiro, known for its award-winning Brazilian Bum Bum Cream body care collection; Elemis, a U.K.-originated professional skin care line distributed in spas and skincare clinics; NuFACE and Dermaflash, two at-home beauty device brands specializing in microcurrent facial toning and gentle exfoliation respectively; and Nutrafol, a legal-strength hair wellness supplement clinically designed to support hair growth.
Further Reading
- Five stocks we like better than Beauty Health
- Samsara Just Answered The AI Question—Is Wall Street Ready To Listen?
- IREN’s 800MW Bet Flips the AI Power Switch
- CrowdStrike Earnings Beat Sparks Selloff—Buy the Dip?
- Tesla’s EV Rebound Leaves Rivian and Lucid Facing a Tougher Investor Test
Receive News & Ratings for Beauty Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beauty Health and related companies with MarketBeat.com's FREE daily email newsletter.
